-
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
2:50
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
-
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
2:50
Key insights on Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
